Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CD34+-enriched HSPCs transduced with lentiviral vector carrying FANCA gene RP-L102

A preparation of autologous CD34+-enriched hematopoietic stem and progenitor cells (HSPCs) from mobilized peripheral blood of patients with Fanconi anemia subtype A (FA-A) that are transduced ex vivo with a lentiviral vector carrying the FANCA gene, with potential to restore FANCA expression and function. Upon re-infusion of autologous CD34+-enriched HSPCs transduced with lentiviral vector carrying FANCA gene RP-L102 back into the patient, these cells express functional FANCA gene. Mutations in the FANCA gene, common in patients with FA, prevent normal DNA repair which may lead to chromosomal breakage, increased sensitivity to oxidative and environmental stress, and bone marrow failure.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CD34+ HSPCs transduced with LV carrying FANCA gene RP-L102
autologous CD34+-enriched hematopoietic stem and progenitor cells transduced with lentiviral vector carrying FANCA gene RP-L102
Code name:RP L102
RPL102
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search